Objective:

To provide a comprehensive overview of paraneoplastic neurological syndromes, emphasizing their epidemiology, immunopathogenesis, clinical spectrum, and current therapeutic strategies, in order to highlight the importance of early recognition and integrated management for improved patient outcomes.

Background:

Paraneoplastic neurological syndromes are a type of immunological disorders affecting the central and peripheral nervous system in the setting of malignancies. Early recognition is crucial because they most commonly manifest before cancer diagnosis. This narrative illustrates a detailed review of the epidemiology, pathogenesis, clinical manifestations, and treatment modalities associated with paraneoplastic neurological syndromes.

Design/Methods:

A comprehensive review of literature was conducted to isolate studies that focus on paraneoplastic syndromes affecting the central and peripheral nervous system. The findings were narratively synthesized with a focus to integrate data on epidemiology, pathophysiology, clinical diagnosis, and current treatment modalities, including immunotherapy and cancer-directed therapy.

Results:

Neurological paraneoplastic syndromes affect a little below 1% of all patients who are diagnosed with cancer, with the highest frequency associated cancer being small cell lung carcinoma (SCLC). It mainly involves immune mediated neuronal damage that are linked with onconeural antibodies. Clinical presentation, and antibody detection provide a clue to the etiology. Some manifestations that are important to note are cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis and encephalomyelitis. Treating the underlying malignancy with supplemental immunosuppressive therapy, is the best treatment modality. Supportive care, including symptomatic relief and rehabilitation, also plays a crucial role in giving rise to better patient outcomes. 

Conclusions:

Early detection and timely intervention are essential for better prognosis in cases of neurological paraneoplastic syndromes. Persistent neurological deficits are seen despite advancements in diagnosis and immunotherapy. Further studies should focus on a robust antibody-based diagnostic algorithm, incorporating a multidisciplinary approach.